All enrolled people who obtained a minimum of one particular dose of zosuquidar or placebo throughout induction had been monitored for the event of adverse occasions (439 individuals, 219 on zosuquidar and 210 on placebo). The commonest adverse situations ended up relevant to the period of extended and sizeable myelosuppression https://kirstenk999grc2.anchor-blog.com/profile